This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold
Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.
Read original at benzingaStocks · News reference
Barclays Maintains Overweight on Madrigal Pharmaceuticals, Lowers Price Target to $962
Barclays analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight and lowers the price target from $964 to $962.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 12:05 PM
- Checked
- Aug 3, 2026, 12:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Filed: 2026-08-12 AccNo: 0001628280-26-055962 Size: 182 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarMadrigal Pharmaceuticals shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform and announced a $605 price target.
Read original at benzingaThis Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinions and price targets for these stocks.
Read original at benzinga